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Abstract
The association of sulfonylurea receptors (SURs) with KIR6.x subunits to form ATP-sensitive K channels presents
perhaps the most unusual function known for members of the transport ATPase family. The integration of these two protein
subunits extends well beyond conferring sensitivity to sulfonylureas. Recent studies indicate SUR-KIR6.x interactions are
critical for all of the properties associated with native KATP channels including quality control over surface expression,
channel kinetics, inhibition and stimulation by Mg-nucleotides and response both to channel blockers like sulfonylureas and
to potassium channel openers. KATP channels are a unique example of the physiologic and medical importance of a transport
ATPase and provide a paradigm for how other members of the family may interact with other ion channels. ß 1999
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
KATP channels are a unique combination of trans-
port ATPases complexed with potassium ion channel
subunits. While the majority of proteins discussed in
this BBA issue on Biomembranes couple the hydrol-
ysis of ATP to movement of molecules across a
membrane against a concentration gradient, KATP
channels, the subject of this article, control the £ux
of potassium ions driven by an electrochemical po-
tential. Control is exerted in response to changes in
the concentrations of cytosolic ADP and ATP that
result from ATP synthesis and hydrolysis within the
cell. This is illustrated diagrammatically in Fig. 1.
ATP hydrolysis is believed to occur as an integral
part of the regulation of KATP channels, but does
not power K movement.
KATP channels are comprised of sulfonylurea re-
ceptors, SURs, and potassium inward recti¢ers,
KIR6.1 and KIR6.2, that assemble to form a large
octameric channel with a (SUR/KIR6.x)4 stoichiom-
etry ([1^3], reviewed in [4]). Some of the evidence
supporting this stoichiometric model is given in
Fig. 2. It is now clear that two gene clusters on the
short arms of human chromosomes 11 and 12 encode
the SUR1 and KIR6.2 subunits, and the SUR2 and
KIR6.1 subunits, respectively. Di¡erential usage of
two terminal exons in the SUR2 gene speci¢es the
two major SUR2A and SUR2B splice variants (re-
viewed in [4,5]). Additional minor splice variants
have been described [6,7]. Based on extensive evi-
dence (reviewed in [4,5,8]) the SUR1/KIR6.2 pairs
are known to comprise the KATP channels of pancre-
atic L-cells, and are found in neurons and neuroen-
docrine cells. The SUR2A/KIR6.2 pair assembles the
channels in cardiac ventricular myocytes and skeletal
muscle [9,10], while SUR2B pairs with KIR6.1 and
KIR6.2 to form the KATP channels found in vascular
and non-vascular smooth muscle [11,12]. Recent re-
ports have suggested that mixed channels comprised
of SUR1/SUR2/KIR6.1 or SUR1/SUR2/KIR6.2 sub-
units may exist [13^16].
The L-cell KATP channels are key players in the
ionic pathway that regulates insulin release in re-
sponse to glucose metabolism. Openings of these
channels can set the resting membrane potential of
L-cells below the threshold for activation of voltage-
gated Ca2 channels when plasma glucose levels are
low, thus reducing insulin secretion (reviewed in
[5,17]). L-Cell KATP channels are the target for sulfo-
nylureas, 1st and 2nd generation hypoglycemic
agents, e.g., tolbutamide, glipizide, and glibenclamide,
used in the treatment of non-insulin dependent diabe-
tes mellitus (NIDDM) to control hyperglycemia, and
for potassium channel openers like diazoxide which is
used to control hyperinsulinemic states. Mutations in
both of the L-cell KATP channel subunits, SUR1 and
KIR6.2, have been shown to cause a recessive form of
familial hyperinsulinism or persistent hyperinsuline-
mic hypoglycemia of infancy, PHHI ([18^21], re-
viewed in [5,17]). The SUR2-based channels are the
targets for a variety of potassium channel openers of
potential therapeutic importance (reviewed in [22^
25]). The SUR2/KIR6.1 gene cluster has not been
linked to a disease at this time.
The high-a⁄nity sulfonylurea receptor, SUR1, was
the ¢rst SUR to be cloned [26]. A biochemical ap-
proach was used to label and purify SUR1 and ob-
tain peptide sequence for cloning. Homology cloning
techniques were then used to obtain SUR1 and
SUR2 cDNAs from various tissues and species.
KIR6.1 was obtained by screening a rat library at
low stringency using a fragment of GIRK1 as a
probe [27]. KIR6.2 was obtained by screening with
the KIR6.1 cDNA as a probe [28]. The predicted top-
ologies of these subunits are shown in Fig. 2. The
KIR subunits have two transmembrane domains
(TMDs), termed M1 and M2, and it is assumed
that the structure of the pore region will closely re-
semble that of the KcsA potassium channel from
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Streptomyces lividans [29], although the precise pack-
ing of the M1 and M2 helices in the KIR family may
di¡er from the bacterial model (see [30]). SUR1 is an
ATP-binding cassette (ABC) protein or transport
ATPase which closely resembles members of the mul-
tidrug resistance associated protein, or MRP, family
with 17 predicted TMDs and two nucleotide binding
folds as illustrated in Fig. 2 ([26,31], reviewed in
[4,5,8,32]).
Neither SUR1 nor KIR6.2 cDNAs produced rec-
ognizable KATP channel activity when expressed
alone, but co-expression generated currents charac-
teristic of native L-cell channels [28,33]. The reason(s)
for this strong co-dependence were not immediately
clear, but did imply either a very strong integration
of the functions of the two subunits, or that parts of
both subunits were required to form the conducting
pathway. Subsequent work has eliminated the latter
possibility, while it has become increasingly clear
that the characteristics of the native channel depend
on subunit-subunit interactions.
Mutations in the M2 helix suggested that KIR6.2
formed the pore [1,34]. A suggestion which was
nicely proven by the demonstration that truncation
of as few as 16 and up to 36 amino acids from the C-
terminus enabled expression of homomeric KIR6.2
channels with the same ion conductance as their het-
eromeric SUR1/KIR6.2 counterparts [35]. Why dele-
tion of a small segment enabled expression was not
clear at the time, but as discussed below, it is now
understood that the truncations removed a critical
tra⁄cking signal.
2. Channel composition and stoichiometry
We established the octameric stoichiometry of
SUR1/KIR6.2 KATP channels, (SUR1/KIR6.2)4
(see Fig. 2), using biochemical and biophysical
methods ([1], reviewed in [4]). Subunits were labeled
with a radioiodinated derivative of glibenclamide,
[125I]iodoazidoglibenclamide [36], and were shown
to be associated with each other by co-puri¢cation
on lectin columns or by using histidine tagged sub-
units and Ni2-agarose [1]. The mature glycosylated
form of SUR1 was observed to be preferentially as-
sociated with KIR6.2, and the molecular mass of the
labeled SUR1/KIR6.2 complex was estimated to be
approx. 950 kDa, matching what was expected for an
octameric (SUR1/KIR6.2)4 complex. One-to-one
SUR1VKIR6.2 fusion constructs generated com-
plexes with the same mass that produced active chan-
nels, but ‘triple’ fusion constructs, SUR1V(KIR6.2)2,
did not unless they were co-expressed with mono-
meric SUR1. Co-expression of triple fusion con-
structs carrying the N160D mutation with the wild-
type triple fusion constructs produced three types of
channels distinguished by their recti¢cation proper-
ties, the parental moderate and strong recti¢ers plus
an intermediate class as expected from a tetrameric
pore. The data were consistent with an octameric
structure as illustrated in Fig. 2. Shyng and Nichols
[3] and Inagaki et al. [2] arrived at the same structure
based on electrophysiological experiments using the
same, or similar, single and triple-fused KATP chan-
nel subunits, respectively.
3. Quality control, subunit tra⁄cking and
ER retention signals
A report by Zerangue et al. [37] has provided in-
sight into how cells maintain quality control over the
assembly of complex proteins like KATP channels.
These authors have shown that protein tra⁄cking
signals, speci¢cally an ^RKR^ motif, can function
Fig. 1. KATP channels respond to changes in ATP/ADP to reg-
ulate K currents driven by a concentration gradient.
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to keep incompletely assembled KATP channels from
reaching the cell surface. This motif is found in the
C-terminus of KIR6.2, the region deleted by Tucker
et al. [35], and in SUR1 upstream from NBF1 (see
the summary illustration in Fig. 14 for the approx-
imate positioning of these signals). A slightly di¡er-
ent motif, ^RKQ^, is found at the equivalent position
in SUR2. Extensive mutational analysis indicated
that changing the ^RKR^ motif to ^AAA^ in either
SUR1 or KIR6.2 allowed their surface expression in
the absence of the partner subunit. Furthermore,
swapping the C-terminus of KIR6.2 onto KIR2.1, a
channel subunit that normally assembles and tra⁄cs
to the plasma membrane, reduced its surface expres-
Fig. 2. Composition and stoichiometry of KATP channels. KATP channels are assembled from a sulfonylurea receptor, SUR, and either
KIR6.1 or KIR6.2 in an octameric stoichiometry. Some of the results which support an octameric model are outlined.
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sion. Zerangue et al. [37] proposed that the ER re-
tention signals were masked during assembly of the
octamer and that only fully assembled channels were
able to reach the plasma membrane thus providing
quality control. These ¢ndings provided an explana-
tion for the earlier observation that the mature gly-
cosylated form of SUR1 was only present when the
receptor was co-expressed with KIR6.1 or KIR6.2 and
that the mature receptor co-puri¢ed with the KIR
subunit [1]. The results also provide a rationale for
the observation by John et al. [38] that high level
over-expression of KIR6.2 alone can give channel ac-
tivity, presumably because the ER retention mecha-
nism is saturable.
4. Anterograde signals and PHHI
In addition to an ER retention signal, the last
amino acids of SUR1 appear to be required for sur-
face expression of L-cell KATP channels. Deletion of
as few as 7 amino acids from the C-terminus of
SUR1 causes a parallel loss of channel activity and
surface expression, although the subunits do associ-
ate [39]. We have proposed that nonsense and splice-
site mutations in SUR1 give rise to PHHI because
the resulting channels never reach the plasma mem-
brane [39]. The ER retention mechanism and require-
ment for an intact SUR C-terminus are summarized
schematically in Fig. 3. This model raises interesting
questions about how the retention and anterograde
signals work and how they are covered and uncov-
ered during assembly of the channel. In addition, the
understanding that tra⁄cking plays a major role in
KATP channel assembly and function has given in-
sight into PHHI and has provided an experimental
means to compare the properties of the pore with
and without SUR.
5. Description of channel activity
The conductance properties and kinetic behavior
of KATP channels have been characterized in some
Fig. 3. Schematic diagram summarizing the assembly and maturation of KATP channels. The scheme for masking of the ^RKR^ ER
retention signals is based on Zerangue et al. [37]. The C-terminus of SUR, designated here as an anterograde signal, is required for
the channels to exit the ER/cis-Golgi compartment as indicated by surface expression and the appearance of complex glycosylated
SUR1 [39]. Deletion of the C-terminus of SUR1 inhibits transit from the ER/cis-Golgi compartment. (Reproduced from [39] with per-
mission.)
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detail [40^42]. As illustrated in Fig. 4, recombinant
SUR1/KIR6.2 channels display a characteristic
‘bursting’ pattern in which the channel rapidly ‘£ick-
ers’ between open and closed states equivalent to
those observed in wild-type channels. The exact
mechanism which gives rise to the fast transitions
within a burst is not known, but based on the char-
acterization of the structure and the dynamics of the
K channel, KcsA, from S. lividans by crystallo-
graphic[29] and spectroscopic methods [43^46] the
short open and closed states are thought to arise
from stochastic movements of the M2 helices that
form the pore and channel gate. Silent interburst
intervals delineate the bursts. As described elsewhere,
expression of the SUR1 and SUR2A subtypes with
KIR6.2 produces channels with di¡erent bursting
properties [4,47]. The data indicate the inward recti-
¢er determines the mean duration of the fast open-
ings and closures within a burst, while the SUR sub-
type determines the rate of transition between bursts
and interburst closed states. The application of ATP,
with or without Mg2, reduces the probability of
¢nding the channel in the open state by prolonging
the lifetime of the interburst closed states and by
shortening the duration of the bursts [10,41,48].
ATP seems to have little e¡ect on the mean duration
of the fast open and closed states within a burst [40],
consistent with SUR modulating the transition from
the bursting to the non-bursting state. Gillis et al.
[49] have proposed a simple kinetic scheme to model
these characteristics (see Fig. 4). In this model,
changes in the apparent sensitivity to ATP could
result from modi¢cations that alter the a⁄nity of
the C2, C3, etc. microstates for nucleotide or from
modi¢cations that alter the dwell time in these micro-
states.
6. Nucleotide e¡ects
The sine qua non of KATP channels is their re-
sponse to nucleotides. Fig. 5 summarizes the actions
of nucleotides on homomeric (KIR6.2vC)4 and het-
eromeric (SUR1/KIR6.2)4 channels. (The interactions
of nucleotides with SUR and KIR subunits and the
importance of these interactions in the actions of
glibenclamide are also covered in the article by
Ueda et al. in this volume.) The conductance of
both channels is equivalent indicating SUR does
not contribute to assembly of the pore [35,47,50].
In the absence of Mg2, conditions under which
ATP will bind tightly to SUR1 [51] but presumably
not undergo hydrolysis, the application of ATP to
either the homomeric or heteromeric con¢guration
results in the inhibition of the spontaneous channel
activity observed in the absence of nucleotides. The
IC50ATP values for inhibition are markedly di¡erent
with the heteromeric channels being approx. 20^40-
fold more sensitive to inhibition by nucleotides
[35,47,50]. In the absence of Mg2, ADP has a sim-
ilar, but less potent inhibitory action on both con¢g-
urations. The Hill coe⁄cients for the nucleotide
dose-response curves are consistently near one imply-
ing one bound nucleotide is enough to inhibit the
passage of K. This e¡ect does not require intact
Fig. 4. Electrical activity of a human SUR1/KIR6.2 ATP-sensi-
tive K channel. Recordings from a membrane patch excised
from a COSm6 cell expressing human SUR1 and human
KIR6.2 illustrate spontaneous channel activity in the absence of
nucleotides. The middle single-channel traces, plotted over a
shorter time interval, show open and closed states within a
burst. The single channel conductance is approx. 75 pS. The ki-
netic model is based on one originally proposed by Gillis et al.
[49].
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nucleotide binding folds as mutations in the Walker
A and B motifs that prevent labeling with 8-azi-
doATP [51] do not a¡ect the IC50ATP values [52,53].
Mg-nucleotides have markedly di¡erent e¡ects on
the two con¢gurations, inhibiting homomeric chan-
nels [35,47,50], while stimulating the heteromeric
channels. Stimulation requires receptors with intact
NBFs; mutations in the Walker A and B motifs
strongly attenuate the e¡ects of MgADP [52,53]. To-
gether these results show that assembly with SUR1
increases the a⁄nity of the nucleotide binding site on
KIR6.2 for ATP, that nucleotide binding to the KIR
inhibits the channel, and that the interaction(s) of
Mg-nucleotides with SUR1 can antagonize this in-
hibition.
7. The cytoplasmic domains of KIR6.2 are important
for nucleotide binding and control of bursting
In addition to their di¡erential responses to nu-
cleotides, the homo- and heteromeric channels di¡er
markedly in their kinetic properties [35,47,50]. Fig. 6
illustrates this point for human (SUR1/KIR6.2)4 vs.
(KIR6.2vC35)4 channels. The single-channel conduc-
tance is the same, but the bursting of the homomeric
channels is qualitatively di¡erent than that of the
heteromeric channels. The ‘bursts’ are extremely
short and the homomeric channels spend far less
time in open states that the heteromeric channels.
In terms of the simple kinetic model in Fig. 4, the
a⁄nity of the long-lived closed state for ATP must
be markedly reduced as the homomeric channels
spend more time in this state, but their IC50ATP is
20^40-fold higher than that of the heteromeric chan-
nels.
The nature of the nucleotide binding site within
KIR6.2 is not clear, but recent e¡orts at its de¢nition
illustrate the complexity of the problem and under-
score the interdependence of the dwell time in a par-
ticular microstate vs. its a⁄nity for nucleotides. Mu-
tations in KIR6.2 which, on the basis of the KcsA
structure, are predicted to be near the mouth of the
pore, for example, K185Q [35], will increase the
IC50ATP values for both homo- and heteromeric
channels without signi¢cantly a¡ecting the Po of
the resulting channels [54]. The K185Q mutation
may therefore be in the nucleotide binding site and
Fig. 5. Nucleotide e¡ects on heteromeric and homomeric KATP channels. The open vertical arrows symbolize K currents which are
equivalent for both con¢gurations. The inhibitory e¡ects of nucleotides acting directly on KIR6.2 are indicated by the solid arrows.
Comparison of the IC50 values implies SUR increases the a⁄nity of KIR6.2 for nucleotides. The open arrow symbolizes stimulation of
channel activity by Mg-nucleotides acting through SUR via a mechanism that requires intact nucleotide binding folds.
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reduce its a⁄nity for ATP; however, it has been
di⁄cult to test the possibility that this mutation is
in a linker between a binding site and the channel
gate. Other mutations, for example an arginine resi-
due, R50, in the N-terminus of KIR6.2 [55] and the
N-terminal deletions described below [56^58] mark-
edly increase the Po by reducing the dwell time in
long-lived closed states. The resulting channels also
show reduced nucleotide sensitivity, but it is unneces-
sary to assume the a⁄nity of the microstate(s) for
ATP has changed. Interestingly, experiments with
8-azidoATP indicate that despite their observed
weak association with ATP, the homomeric channels
can be photolabeled [59] and should provide a means
to determine what amino acids are in proximity to
the adenine ring. Drain [50] has presented evidence
suggesting the sequence from 333 to 338 which re-
sembles the F-X4-K sequence found in ion-motive
ATPases is a candidate ATP binding site.
Modi¢cations of the N-terminus of KIR6.2 have
marked e¡ects on KATP channel kinetics [56^58].
We have shown that deletion of 5^44 amino acids
a¡ects the maximum open probability, Pomax, of
the SUR1/vNKIR6.2 channels as illustrated in Fig.
7. The estimated Pomax is that expected if the SUR1/
vNKIR6.2 channels are in an in¢nitely long burst
having the same intraburst kinetics as the wild-type
channels. As would be expected from the reduced
Fig. 6. Comparison of wild-type and truncated KATP channels. Single channel records from homomeric channels, KIR6.2vC35, ob-
tained by deleting 35 amino acids, containing the ^RKR^ ER retention motif from the C-terminus of KIR6.2, from heteromeric
SUR1/KIR6.2 channels and from SUR1/KIR6.2vC35 channels are presented. The (KIR6.2vC35)4 channels show abnormal bursting
and have a markedly reduced probability of being in an open state. The maximal open probability, Po, estimated from the all points
histogram, is approx. 8-fold lower than the wild-type channels. Co-expression of KIR6.2vC35 with SUR1 restores normal bursting, in-
creasing the maximal Po. The horizontal dotted lines give the zero-current level ; the upward de£ections correspond to outwardly di-
rected currents. (Reproduced from [54] with permission.)
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occupancy of the nucleotide-binding interburst
closed state, the IC50ATP for these channels is in-
creased approx. 20-fold, as discussed above. The
data are consistent with the idea that the a⁄nity of
the closed state for ATP need not be altered. We
have proposed that the N-terminus of KIR normally
limits the duration of a burst and suggested it could
couple conformational changes in SUR to the pore/
gate. The structural question of how the N-terminus
actually limits bursting and what part(s) of the gate
are involved is unanswered.
8. Chimeric KATP channels are revealing functionally
important regions of the receptors
The L-cell and cardiac channels di¡er in their ki-
netics and sensitivity to modulators including ATP,
sulfonylureas and potassium channel openers. Ad-
vantage is being taken of these di¡erences to delin-
eate the regions of the receptors that specify the iso-
form di¡erences. We have used SUR1VSUR2A
chimeras to de¢ne the regions which specify the iso-
form di¡erences in channel kinetics and sensitivity to
ATP [47]. An example is given in Fig. 8. The longer
burst duration and greater Pomax of the cardiac
SUR2A/KIR6.2 channels is speci¢ed by an N-termi-
nal segment of the SUR2A receptor, while the lower
IC50ATP of the L-cell channel is speci¢ed by a C-
terminal segment. Using a matched set of chimeric
constructs, the N-terminal segment was identi¢ed as
the SUR2 TMD1-5 region while the C-terminal seg-
ment was identi¢ed as the last 42 amino acids of
SUR1 [47]. Interestingly, the isoform di¡erences in
kinetics and ATP sensitivity were separable indicat-
ing that the di¡erence in ATP sensitivity is not due
to a decreased occupation of the interburst closed
state. These results imply that the SUR TMD1-5
segment is in close proximity to KIR6.2 and is in a
position to modulate bursting. We have speculated
this could result from interactions with the KIR N-
terminus [47].
Fig. 7. Amino terminal deletion of KIR6.2 generates KATP channels that burst continuously. The upper panel shows an example of
the macro-currents activated upon excision of an inside-out patch taken from a COSm6 cell co-transfected with SUR1 and
vN44KIR6.2. The single channel recordings in the two lower panels show these channels are less sensitive to ATP and burst nearly
continuously with the Po value expected for an unmodi¢ed wild-type channel in an in¢nitely long burst. We have proposed the lower
ATP sensitivity of these channels is the result of their spending less time in interburst closed states able to bind ATP.
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9. How do potassium channel openers work?
Potassium channel openers (KCOs) increase the Po
of heteromeric, but not homomeric KATP channels
(see Fig. 9). Recent studies using [3H]P1075, a potent
activator of vascular smooth muscle KATP channels
[60,61], suggest that KCOs bind to a speci¢c confor-
mation of sulfonylurea receptors. Switching SURs
into this conformation requires a divalent cation
(Mg2 or Mn2) and a hydrolyzable nucleotide
[62^65]. Mutations in the NBFs strongly inhibit
[3H]P1075 binding which, along with the requirement
for divalent cations and a hydrolyzable nucleotide,
strongly suggest hydrolysis is required for the con-
formational change in the receptor. Glibenclamide
inhibits [3H]P1075 binding by increasing its rate of
dissociation from SURs [62^64]. KCO binding is also
inhibited by thiol-modifying reagents [66], perhaps
by reaction with the cysteine in NBF1. Competition
studies using [3H]P1075 and a variety of other KCOs
show rank order of potency consistent with physio-
logic observations, while binding to the di¡erent re-
ceptor isoforms indicates the a⁄nity of SUR2B is
greatest, consistent with this receptor being a sub-
unit of vascular smooth muscle KATP channels [11,
63,65].
Fig. 9. Diazoxide stimulation of channel activity requires SUR. The open vertical arrows symbolize K currents. Diazoxide and other
potassium channel openers do not a¡ect the homomeric channels. Stimulation of heteromeric channels requires divalent cations, hy-
drolyzable nucleotides and intact nucleotide binding folds on the SUR.
Fig. 8. Chimeric SUR/KIR6.2 channels have the combined properties of L-cell and cardiac KATP channels. The upper set of panels (A)
compares the properties of the parental SUR1/KIR6.2 L-cell and SUR2A/KIR6.2 cardiac KATP channels. The two channel isoforms are
distinguishable by their Po values, the average burst duration (Tb2ms) and IC50ATP values. The lower set of panels (B) illustrates the
mixed properties of one pair of matched chimeric channels. The swapped segments from the L-cell and cardiac receptors are shown in
black and gray, respectively. The intraburst kinetics are not a¡ected by these swaps. The SUR2AVSUR1/KIR6.2 channels exhibit the
higher Po and longer burst duration of the cardiac channel with the lower IC50ATP of the L-cell channel. The SUR1VSUR2A/
KIR6.2 channels exhibit the reciprocal characteristics. Analysis of a more extensive collection of SUR chimeras identi¢es the SUR
TMD1^5 segment as critical for speci¢cation of the isoform kinetics, while the last 42 amino acids specify the IC50ATP values.
6
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10. A two-step mechanism for the action of
sulfonylureas
Sulfonylureas are well known to bind to receptors
in a variety of tissues (see [5,8,67] for reviews). The
Kd values for binding to the high-a⁄nity receptor
identi¢ed in pancreatic L-cells and in brain are in
the low WM range for tolbutamide and in the low
nM for glibenclamide. The estimated Kd values for
sulfonylurea binding to the SUR2 receptors show
their a⁄nities are typically about a thousand-fold
weaker than SUR1 for these compounds (see for
example a recent comparison of binding data from
expressed recombinant receptors [68]). Fig. 10 sum-
marizes the multi-step nature of the e¡ects of sulfo-
nylureas on L-cell KATP channel activity. High con-
centrations of tolbutamide, the 1st generation of
hypoglycemic sulfonylureas whose actions are rap-
idly reversible, will inhibit homomeric channels, but
this e¡ect is of unknown physiologic importance as
concentrations of this compound are never expected
to reach these levels [69]. The heteromeric channels
are approximately a thousand-fold more sensitive to
inhibition by tolbutamide. The dose-response curves
for tolbutamide inhibition of SUR1/KIR6.2 vs.
SUR2A/KIR6.2 channels show a large spread in
IC50 values and demonstrate that the L-cell channels
have two components of inhibition, one of high af-
¢nity, which is saturated at a value near 100 WM, the
other of low a⁄nity, IC50s 1.5 mM ([69,70], illus-
trated in Fig. 11). The low-a⁄nity component has
been attributed to a direct action on KIR6.2 [69].
The situation is not clear for the SUR2A/KIR6.2
channels since the estimated Kd for binding of tolbu-
tamide to SUR2A is approx. 0.3 mM [68] and sim-
ulations using two components with Kd values of 0.3
and 1.5 mM indicate the available data are not su⁄-
cient to eliminate a contribution of SUR2A in the
inhibition of the cardiac channel.
The high-a⁄nity inhibition seen in the L-cell chan-
Fig. 10. Sulfonylureas have multiple inhibitory e¡ects on KATP channels. The e¡ects of the readily reversible 1st generation sulfonylur-
ea, tolbutamide, are illustrated. The solid arrows indicate direct inhibitory actions on the homomeric and heteromeric channels in the
absence of the stimulatory e¡ects of Mg-nucleotides, respectively. The IC50 values di¡er markedly; the high-a⁄nity e¡ect on the het-
eromeric channel requires SUR1, or a segment of SUR1, and an intact N-terminus on KIR6.2. The binding of tolbutamide to a KATP
channel in vivo causes a conformational change that blocks the stimulatory action of Mg-nucleotides as symbolized by the dashed ar-
row. This stimulatory action normally antagonizes the inhibitory e¡ects of nucleotides on KIR6.2, thus its elimination augments the ef-
fect of tolbutamide. The overall e¡ect is additive, the sum of the direct inhibitory e¡ect of tolbutamide and the inhibitory e¡ect of
Mg-nucleotides on KIR6.2 (symbolized by the dotted arrow) which are no longer antagonized by SUR1.
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nels, which is the basis for their selective response to
sulfonylureas, is a two-step process. In excised
patches, in the absence of stimulation by Mg-nucleo-
tides, tolbutamide reduces channel activity by ap-
prox. 50^60% (Fig. 11). This inhibition involves the
N-terminus of KIR6.2 since deletion of 5 amino acids
from KIR6.2 reduces the e¡ect of tolbutamide while
deletion of ten or more residues essentially eliminates
the inhibitory e¡ect [58,70]. The results suggest a
mechanism in which the binding of tolbutamide to
SUR1 results in a conformational change that is
linked to, and closes the pore by a process that
must involve the N-terminus of KIR6.2.
The second e¡ect of the tolbutamide-induced con-
formational change is the elimination of the stimula-
tory e¡ect of Mg-nucleotides. The inhibition of L-cell
KATP channels by sulfonylureas has been reported
to be ‘enhanced’ by the presence of Mg-nucleotides
[71^73]. This e¡ect is illustrated in Fig. 12. Note that
the activity (the relative NPo values) of channels in
the presence of ADP and ATP (at approximately
intracellular concentrations, c in Fig. 12) is reduced
s 80% by tolbutamide under stimulatory conditions
with Mg2 present, but is less than 40% inhibited
when Mg2 is absent. These experiments were done
using 200 WM tolbutamide, a concentration su⁄cient
to saturate the high-a⁄nity binding site on SUR1.
The ¢nal NPo values, in the presence of tolbutamide,
were essentially the same whether the channels were
stimulated or not. These results are consistent with
the idea that tolbutamide acts to disrupt the stimu-
lation of the L-cell channels by Mg-nucleotides. As
indicated above, the stimulatory action of nucleo-
tides, through their interactions with SUR, normally
antagonize their own inhibitory action on the KIR.
6
Fig. 11. SUR1 speci¢es the high-a⁄nity tolbutamide inhibition
of KATP channels. A comparison of the currents, and dose-re-
sponse curves, from SUR1/KIR6.2 vs. SUR2A/KIR6.2 KATP
channels in response to the application of tolbutamide indicates
the L-cell channel has two components, while inhibition of the
cardiac channel can be described by a single component. The
high-a⁄nity component of the SUR1/KIR6.2 channels, which
accounts for approx. 55% of the total current, is saturated near
100 WM. The solid curve through the SUR1/KIR6.2 data is the
best ¢t to a two component pseudo-Hill equation giving
IC50H = 1.9 þ 0.2 WM, hH = 1.04 þ 0.08, IC50L = 1399 þ 137.3 WM,
hL = 1.13 þ 0.1. The dashed line through the SUR2A/KIR6.2
data is the best ¢t to a single component pseudo-Hill equation
giving IC50 = 1057.4 þ 52.1 WM, and h = 0.95 þ 0.04. These ex-
periments were done without nucleotides in a Mg2-containing
internal solution [70]. Tlb, tolbutamide. (B) Structures of gliben-
clamide, meglitinide and tolbutamide drawn to illustrate that
glibenclamide contains two moieties both of which can bind to
SURs and inhibit KATP channel activity. (Adapted from [70]
with permission.)
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Disrupting stimulation thus reveals the inhibitory ef-
fects of nucleotides which then become additive with
the direct tolbutamide e¡ect observed when nucleo-
tides are absent. This results in the IC50 for sulfonyl-
urea inhibition appearing to be a function of nucleo-
tide concentration, and underlies the increased
e⁄cacy of sulfonylureas seen in intact cells (for ex-
ample [74]).
The segment of SUR1 that is necessary for high-
a⁄nity tolbutamide inhibition has been identi¢ed us-
ing chimeric SURs [70,75]. Fig. 13 illustrates this
localization using our matched set of SUR chimeras.
Inclusion of the SUR1 TMD12^17 segment in a
SUR2A background is su⁄cient to confer high a⁄n-
ity inhibition by tolbutamide. Inclusion of a smaller
segment, TMD12^15, ChimXVIII, confers inhibi-
tion, but the IC50 for tolbutamide is increased, con-
sistent with the TMD12^17 segment containing the
sulfonylurea binding site. Comparison of their Pomax
values demonstrates that swapping the TMD12^17
segments does not a¡ect the kinetics of the chimeric
channels indicating that the increased sensitivity to
tolbutamide is not the result of increased occupation
of a kinetic state that binds sulfonylureas.
Fig. 14 provides a summary. The top panel sum-
marizes the studies aimed at mapping the structural
determinants of various characteristics of KATP chan-
nels. The model in the lower panel incorporates
many of these features of KATP channels and spec-
ulates on potential interactions between the SUR and
KIR6.x subunits. Two pairs of SUR/KIR6.2 subunits
are illustrated centered around the pore. The SURs
are depicted surrounding KIR6.2 consistent with
there being no indication that SURs contribute to
the permeation pathway. We have used our chimeric
channel data to position the TMD1^5 and 12^17
segments. As TMD1^5 speci¢es the isoform di¡er-
ences in gating kinetics we assume this requires close
Fig. 12. Tolbutamide binding uncouples the Mg-nucleotide dependent stimulatory action of SUR1 on KIR6.2. A concentration of tol-
butamide su⁄cient to saturate the high-a⁄nity component was used to probe conventional inside-out patches containing approxi-
mately a thousand KATP channels. Current measurements were made at the indicated Mg-nucleotide concentrations to provide varying
degrees of stimulation (shaded bars). Mg2 was removed with EDTA to eliminate stimulation (open bars). The degree of stimulation
can be estimated from the heights of the shaded vs. open bars in the absence of tolbutamide. The ‘enhancement’ of tolbutamide inhib-
ition (see also [72,73]) by nucleotides can be judged by comparing the degree of inhibition under stimulated (shaded bars) and unsti-
mulated (open bars) conditions. The apparent increase in e⁄cacy is the additive e¡ect of inhibition by tolbutamide and by Mg-nucleo-
tides after eliminating the nucleotide stimulatory e¡ect. Note the scales of the relative NPo values are di¡erent. The relative NPo
values after tolbutamide inhibition in Mg2 containing and Mg2-free conditions are not signi¢cantly di¡erent as judged by Student’s
t-test. A plot of the tolbutamide-induced decrease in NPo in the presence of Mg-nucleotide(s) vs. the Mg-nucleotide stimulated in-
crease in NPo shows a correlation. The alphabetical symbols correspond to the individual experiments. The solid line is a linear re-
gression, the dashed lines give the 95% con¢dence limits. (Adapted from [70] with permission.)
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Fig. 13. Chimeric SURs de¢ne the SUR1 segment required for high-a⁄nity tolbutamide inhibition of KATP channels. The top panel
shows tolbutamide inhibition of channels assembled from KIR6.2 and the parental and chimeric SURs illustrated. The matched chime-
ras I through VI and IX through XIV were described in a previous report [47]. Segments from SUR1 and SUR2A are shown in black
and gray respectively; topological features are indicated on the left axis, amino acid residues are on the right. The presence of the
TMD12^17 segment of SUR1 is su⁄cient to confer a high-a⁄nity interaction between tolbutamide and the chimeric receptor. The re-
cording shows an example of inhibition of the ChimXVII/KIR6.2 channels which have the SUR2 TMD1^5 segment and display the
high Pomax characteristic of cardiac KATP channels. The dose-response curves for the Chim XVII/KIR6.2 and Chim XVIII/KIR6.2
channels show that the presence of the TMD12^17 segment of SUR1 is su⁄cient to specify a high a⁄nity interaction with tolbuta-
mide (IC50H = 2.2 þ 0.3 WM, hH = 1.11 þ 0.11, IC50L = 1374.1 þ 393.2 WM, hL = 0.97 þ 0.21, compare with the values for SUR1 in Fig.
11). Reducing the size of the swapped segment reduces the apparent a⁄nity of the chimeric channel for tolbutamide
(IC50H = 16.7 þ 4.3 WM, hH = 1.18 þ 0.19, IC50L = 1504.6 þ 914.5 WM, and hL = 1.01 þ 0.37) without signi¢cantly a¡ecting the apparent ef-
¢cacy. (Adapted from [70] with permission.)
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association with the M2 helix. Similarly we have
positioned the C-terminus of SUR near the C-termi-
nal cytoplasmic segment of KIR6.2 based on the gen-
eral idea that the KIR C-terminus carries the low
a⁄nity nucleotide binding site and that the SUR
C-terminus speci¢es the isoform di¡erences in
IC50ATP [70]. The structure of the KIR pore is mod-
eled on the KcsA channel described by Doyle et al.
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[29] without implying an exact packing of M1 and
M2: the K selectivity ¢lter is formed by the back-
bone carbonyl groups ( = O) of the ^GFG^ motif.
Two dehydrated K ions (smaller spheres) occupy
the two sites within the ¢lter; larger hydrated K
ions are positioned on either side of the ¢lter. The
M2 helices line the aqueous pore within the trans-
membrane electrical ¢eld. ‘Gated access’ [79] to the
pore is believed to be controlled by rigid movements
of the M2 helix and possibly an adjacent segment of
the C-terminus [43,46]. We have indicated movement
of the internal helices by their di¡erent positions in
the right vs. left halves of the channel. The left pair is
illustrated in an open state with the M2 helix posi-
tioned to allow access to the pore. No nucleotide is
shown on KIR6.2 in the open pore state, although
there are no data on this point; both NBFs on
SUR are occupied, and are shown to be interacting,
as they presumably are in vivo. The right pair illus-
trates a glibenclamide-induced closed state. The gli-
benclamide binding site is proposed to consist of a
benzamido (meglitinide) binding site (dotted ring) on
TMD1^5 and the sulfonylurea (tolbutamide) binding
site on TMD12^17 consistent with earlier observa-
tions on photolabeling with [125I]iodoglibenclamide
[26] and the data presented here and in [75]. Inter-
action with both the benzamido and sulfonylurea
binding sites could account for the several thou-
sand-fold increase in a⁄nity of glibenclamide vs. tol-
butamide. Cooperative interactions between NBF1
and NBF2 are shown as disrupted by the conforma-
tional change (shown here for illustrative purposes as
a change in the orientation of the TMD1^5 and 12^
17 segments) induced by sulfonylurea binding, con-
sistent with the observations of Ueda et al. [76]. This
conformational change repositions the M2 helix to a
closed state via a mechanism that requires an intact
N-terminus on KIR6.2.
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